ERBB2 and breast carcinoma: In the prospective, single-arm, phase 2 DEBBRAH trial (NCT04420598), the efficacy and safety of T-DXd was assessed in patients with HER2-low advanced breast cancer with asymptomatic untreated or progressing BMs after local therapy (n = 12).